Resources

  • References


    About MS.
    National Multiple Sclerosis Society website. Available at:
    http://nationalmssociety.org/about-multiple-sclerosis/index.aspx. Accessed September 5, 2013.

    Ascherio A, et al. Vitamin D and multiple sclerosis.
    Lancet Neurol. 2010;9(6):599-612.

    Cohen JA, Barkhof F, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    N Engl J Med. 2010;362(5):402-415.


    FDA approves Ampyra to improve walking in adults with multiple sclerosis. US Food and Drug Administration website. Available at:
    http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm198463.htm. Updated April 25, 2013. Accessed September 5, 2013.

    International Multiple Sclerosis Genetics Consortium. Risk alleles for multiple sclerosis identified by a genomewide study.
    NEJM.
    2007;357(9):851-862.


    Kasper DL, Braunwald E, et al.
    Harrison’s Principles of Internal Medicine. 16th ed. The McGraw-Hill Companies; 2006.

    Kappos L, Radue EW. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    N Eng J Med. 2010;362(5):387-401.


    Multiple sclerosis. EBSCO DynaMed website. Available at:
    http://www.ebscohost.com/dynamed. Updated August 5, 2013. Accessed September 5, 2013.


    NINDS multiple sclerosis information page.
    National Institute of Neurological Disorders and Stroke
    website. Available at:
    http://www.ninds.nih.gov/disorders/multiple%5Fsclerosis/multiple%5Fsclerosis.htm.
    Updated July 5, 2013. Accessed September 5, 2013.

    Rose JW, Carlson NG. Pathogenesis of multiple sclerosis.
    Continuum Lifelong Learning Neurol.
    2007;13:35-62.


    Treatments. National Multiple Sclerosis Society. Available at
    http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/treatments/index.aspx. Accessed September 5, 2013.

    Van der Mae IA, et al. Individual and joint action of environmental risk factors and MS.
    Neurol Clin. 2011;29:233-55.


    1/4/2011 DynaMed Systematic Literature Surveillance
    http://www.ebscohost.com/dynamed: Healy B, Ali E, Guttmann C, et al. Smoking and disease progression in multiple sclerosis.
    Arch Neurol.
    2009;66(7):858-864.


    1/4/2011 DynaMed's Systematic Literature Surveillance
    http://www.ebscohost.com/dynamed: US Food and Drug Administration. FDA approves first oral drug to reduce MS relapses. US Food and Drug Administration website. Available at:
    http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm226755.htm.
    Updated April 19, 2013. Accessed September 5, 2013.


    1/4/2011 DynaMed's Systematic Literature Surveillance
    http://www.ebscohost.com/dynamed: Kang JH, Sheu JJ, Kao S, Lin HC. Increased risk of multiple sclerosis following herpes zoster: a nationwide, population-based study.
    J Infect Dis.
    2011;204(2):188-92.

    4/25/2014 DynaMed's Systematic Literature Surveillance http://www.ebscohost.com/dynamed: Rosti-Otajärvi EM, Hämäläinen PI.
    Neuropsychological rehabilitation for multiple sclerosis.
    Cochrane Database Syst Rev. 2014;2:CD009131.

    4/25/2014 DynaMed's Systematic Literature Surveillance http://www.ebscohost.com/dynamed: Yadav V, Bever C Jr, et al. Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(12):1083-1092.

  • Resources

    Multiple Sclerosis Association of America

    http://www.mymsaa.org

    National Multiple Sclerosis Society

    http://www.nationalmssociety.org

  • Canadian Resources

    Multiple Sclerosis Society of Canada

    http://mssociety.ca